Table 4.
Long-Term Pooled OCS Exacerbation Rates with ICS/LABA Combinations*
| OCS exacerbation rate | |||
|---|---|---|---|
| ICS/LABA combination | n / N | % | 95% confidence interval |
| Fluticasone/formoterola | 16 / 752 | 2.1 | 1.1, 3.2 |
| Fluticasone/formoterolb | 22 / 752 | 2.9 | 1.7, 4.1 |
| Fluticasone/salmeterol [Lasserson, 2011 (32)] | 239 / 2516 | 9.5 | 8.4, 10.6 |
| Budesonide/formoterol [Lasserson, 2011 (32)] | 257 / 2433 | 10.6 | 9.3, 11.8 |
| ICS/LABA combinations [Ducharme, 2010 (22)] | 258 / 1615 | 16.0 | 14.2, 17.8 |
| ICS/LABA combinations [Chauhan, 2014 (33)] | 275 / 1643 | 16.7 | 14.9, 18.5 |
*
Derived from fluticasone/formoterol studies and meta-analyses by Lasserson et al., 2011, Ducharme et al., 2010, and Chauhan and Ducharme, 2014.
OCS exacerbation, oral corticosteroid-requiring exacerbation.
a
Pooled OCS exacerbation rate from Studies 1 and 2 (main analysis includes patients with an exacerbation treated with an oral, intramuscular, or intravenous corticosteroid); bPooled severe exacerbation rate from Studies 1 and 2 (sensitivity analysis includes patients treated with oral, intramuscular, or intravenous corticosteroid for any respiratory illness).